報價延遲最少15分鐘:2025/07/18 16:30 EDT
盤後時段
|
||||
|
5.39 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.39
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.80/-0.30
|
|
企業價值
1.25B
|
| 資產負債 |
|
每股賬面淨值
3.35
|
| 現金流量 |
|
現金流量率
0.15
|
| 損益表 |
|
收益
53.76M
|
|
每股收益
0.18
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/18 16:30 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases. |
